In a placebo-controlled phase 2 trial of tivantinib plus erlotinib in 167 unselected, previously treated patients with advanced NSCLC, tivantinib/erlotinib recipients with wild-type EGFR had numerically improved PFS (P = 0.25) and OS (P = 0.25) 60. Here, EGFR is linked to non-small cell lung carcinoma.